8 years ago

Orchard Therapeutics Raises $110 Million in Series B Funding to Advance Gene Therapies for Rare Disorders

  • Orchard Therapeutics, a London, UK- and California, US-based biotechnology company dedicated to treating rare disorders through innovative gene therapies, has completed a $110 million Series B financing

  • The round was co-led by Baillie Gifford and ORI Capital with participation from Temasek and Cowen Healthcare Investments, alongside Juda Capital, Pavilion Capital, RTW Investments, Agent Capital, 4BIO Capital and existing investors F-Prime Capital and UCL Technology Fund

  • The company intends to use the funds to progress its pipeline, including the global launch of OTL-101, and to expand their manufacturing infrastructure and business development activity

  • The company is advancing its lead product, OTL-101, an autologous ex-vivo lentiviral gene therapy in development for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID), a rare and life-threatening inherited disorder of the immune system

  • OTL-101 has been granted Breakthrough Therapy Designation by the FDA and is currently in late stage clinical development.

      • ProblemHealthcare

      "People with rare disorders such as adenosine deaminase severe combined immunodeficiency (ADA-SCID) have limited treatment options and often struggle with life-threatening health issues."

      Solution

      "Orchard Therapeutics is developing innovative gene therapies to treat these rare disorders, starting with OTL-101 for ADA-SCID, and expanding its pipeline to include other conditions such as X-linked chronic granulomatous disease (X-CGD), metabolic diseases, and more."

      Covered on